Company intelligence / Profile preview
Mosanna Therapeutics
Basel, Basel-City, Switzerlandmosanna.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Mosanna Therapeutics’ lead candidate, MOS-118, is being developed as a pharmacologic therapy for metabolic obstructive sleep apnea. The company recently announced seed extension financing to complete preparations for entering clinical trials. No clinical results have been reported yet as they are preclinical.
- Therapeutic areas
- Metabolic Disorders
- Modalities
- small molecules (specifically, a medicinal nasal spray)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Seed financing led by Forty51 Venturesuses contract research organizations for development work
Beyond the preview
Go deeper on Mosanna Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mosanna Therapeutics.